Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 265Active not recruiting 156Terminated 12Recruiting 9No longer available 3Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

toripalimab 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Has announcements × Clear all
NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
401 enrolled 1 FDA
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡